Meanwhile, Robert et al. demonstrated that patients with reduced SLC7A11 expression have longer survival than patients with elevated SLC7A11 levels and the high expression level of SLC7A11 is associated with accelerated tumor growth and predicts poor survival in patients with malignant glioma [30]. This evidence concerns the gene SLC7A11 and malignant glioma.